CytomX Therapeutics (CTMX) Provides Business Update and Outlines 2023 Goals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities
January 5, 2023 4:05 PM EST- CX-2029 (CD71 conditionally activated ADC) continued to demonstrate encouraging anti-cancer activity in squamous tumors in the now completed Phase 2 Cohort Expansion Study. AbbVie and CytomX to determine next steps for program in 2023 -
- CytomX and Moderna announce today, separately, a strategic collaboration to research and develop messenger RNA-based conditionally activated therapeutics -
- Broad pipeline progress anticipated in 2023 including continued advancement of clinical stage partnered programs, filing of two INDs for next generation wholly owned programs and broadening of R&D activities... More
